New antibody drug formulation wins novel MHRA approval
05 March 2024
A new formulation of an antibody drug has been authorised via a process from the Medicines and Healthcare products Regulatory Agency (MHRA) that enables “considerably shorter” approval timelines.
A new center for testing drugs on laboratory animals is being considered
04 March 2024
According to Alexey Kochetov, Director of the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, the establishment of national bioresource centers is essential for the generation of genetic lines of laboratory animals to facilitate the advancement of new drugs and preclinical research. Such a step is rational in view of the course towards achieving Russian technological sovereignty in pharmacology and medicine.
A new chapter for biotech: Confidence returns to the market
04 March 2024
After a few years characterised by uncertainty, the narrative across the biotech industry is changing. We have seen a steady upswell in optimism among biotech organisations and other stakeholders over the recent months as new activity announcements set the tone for a ‘return to normal’. The Financial Times noted that the US biotech sector is bouncing back, quoting data from Jeffries that shows January’s capital raised ($6.2bn) reached levels similar to the previous high-water mark of February 2021.
Russia has developed a test that can detect 2,500 hereditary diseases in infants
01 March 2024
A test system has been developed by Russian scientists that can identify approximately 2,500 hereditary diseases in newborns within the first days of their lives. Prime Minister Mikhail Mishustin spoke about this at a strategic session dedicated to socio-economic development.
440 million rubles have been assigned for the bone marrow donation program
01 March 2024
The Russian Prime Minister, Mikhail Mishustin, has approved the allocation of 440 million rubles from the federal budget to bolster the progress of bone marrow and hematopoietic stem cell donation. According to the government website, these funds will be utilized to enhance the accessibility of cutting-edge medical care for patients.
Overcoming challenges of continuous antibody manufacture
29 February 2024
During monoclonal antibody (mAb) manufacture, continuous flowsheets could offer ~20 percent–40 percent cost of goods (COG) saving over the batch process, for instance, during low commercial demand, a paper suggests.
Single-use technology propelling upstream bioprocessing market expansion
29 February 2024
A driving factor behind the expansion of the upstream bioprocessing market is the need for process improvement in the biopharma industry,, research highlights.
Novel immunotherapy approved for melanoma
28 February 2024
The first non-CAR-T adoptive cell therapy to reach the market has been approved by the US Food and Drug Administration (FDA).
EMA and HMA Launch Real-Word Data Catalogues
28 February 2024
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) announced on Feb. 15, 2024 that they have launched two public electronic catalogues for real-word data (RWD). The RWD catalogues will help regulators, researchers, and pharmaceutical companies identify suitable data sources for research and assessment of study protocols and results.
WHO initiative to enhance biomanufacturing in LMICs
27 February 2024
The World Health Organization (WHO) has launched a new Biomanufacturing Workforce Training Initiative to help overcome challenges within the biomanufacturing sector in low- and middle-income countries’ (LMICs). The programme aims to support the limited capacity within the industry in LMICs.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024